PEAK6 Group’s Ionis Pharmaceuticals IONS Stock Holding History

PEAK6 Group’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$71K	Sell	1,700 -4,600	-73%	-$204K	﹤0.01%	3821
2018 Q1	$278K	Buy	6,300 +700	+13%	+$35.6K	﹤0.01%	3103
2017 Q4	$282K	Buy	+5,600	New	+$307K	﹤0.01%	2926
2017 Q1	–	Sell	-14,600	Closed	-$698K	–	4607
2016 Q4	$698K	Buy	14,600 +1,500	+11%	+$59.4K	0.01%	2192
2016 Q3	$480K	Buy	+13,100	New	+$410K	﹤0.01%	2379
2016 Q1	–	Sell	-3,500	Closed	-$217K	–	4692
2015 Q4	$217K	Buy	3,500 +1,800	+106%	+$97.1K	﹤0.01%	3378
2015 Q3	$69K	Sell	1,700 -13,400	-89%	-$694K	﹤0.01%	4520
2015 Q2	$869K	Sell	15,100 -129,500	-90%	-$8.23M	0.01%	2231
2015 Q1	$9.21M	Sell	144,600 -86,500	-37%	-$5.87M	0.07%	361
2014 Q4	$14.3M	Buy	+231,100	New	+$11.4M	0.11%	204
2014 Q3	–	Sell	-20,000	Closed	-$689K	–	4892
2014 Q2	$689K	Buy	+20,000	New	+$630K	0.01%	2003

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

PEAK6 Group's IONS Position: Q2 2018 in Review

PEAK6 Group increased its Ionis Pharmaceuticals (IONS) stake by 116% in Q2 2018, buying an estimated $470K and bringing the position to 19,786 shares worth $824K. The position accounts for ﹤0.01% of the portfolio, ranked #2134.

PEAK6 Group first reported a position in IONS in Q2 2013 and has held it in 8 quarters since. 307 funds tracked by Wall St. Rank hold IONS as of Q2 2018.

PEAK6 Group held 19,786 shares of Ionis Pharmaceuticals worth $824K as of Q2 2018.
PEAK6 Group bought 10,610 Ionis Pharmaceuticals shares in Q2 2018, an estimated $470K.
Ionis Pharmaceuticals made up ﹤0.01% of PEAK6 Group's portfolio in Q2 2018, its #2134 holding.
PEAK6 Group first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 8 quarters since.
307 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.